# MDCX (Medicus Pharma Ltd.) - SEC EDGAR Financial Statements

> Medicus Pharma Ltd. reported $14.54M in total assets and a net loss of $50.91M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/MDCX
- Markdown: https://convexityos.com/fundamentals/MDCX.md
- SEC CIK: 0001997296
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:11 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001997296&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$42.33M | Operating profit |
| Net Income | FY 2025 | -$50.91M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$39.03 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $5.02M | Total debt: $108K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Research & Development | $7.72M | $3.53M | $194K |
| Total Operating Expenses | $34.36M | $11.18M | $4.73M |
| **Operating Income** | -$34.36M | -$11.18M | -$4.73M |
| Income Tax Expense | $0 | $0 | $0 |
| **Net Income** | -$47.28M | -$11.16M | -$5.31M |
| Basic EPS | -$137.00 | -$58.00 | -$76.50 |
| **Diluted EPS** | -$137.00 | -$58.00 | -$76.50 |
| Basic Shares Outstanding | 345.7K | 192.4K | 69.6K |
| Diluted Shares Outstanding | 345.7K | 192.4K | 69.6K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $1.95M | $4.91M | $2.70M | $2.59M | $1.68M | $1.44M | $2.01M | $1.37M |
| Total Operating Expenses | $14.46M | $11.48M | $8.60M | $7.79M | $15.43M | $6.02M | $5.13M | $3.59M |
| **Operating Income** | -$14.46M | -$11.48M | -$8.60M | -$7.79M | -$15.43M | -$6.02M | -$5.13M | -$3.59M |
| Interest Expense | -- | $206K | $375K | -- | -- | $0 | $0 | -- |
| **Net Income** | -$15.18M | -$11.62M | -$9.04M | -$15.07M | -$20.94M | -$6.18M | -$5.10M | -$3.54M |
| Basic EPS | -$11.64 | -$10.50 | -$15.50 | -- | -$56.18 | -$21.50 | -$21.00 | -- |
| **Diluted EPS** | -$11.64 | -$10.50 | -$15.50 | -- | -$56.18 | -$21.50 | -$21.00 | -- |
| Basic Shares Outstanding | 1.3M | 1.1M | 590.8K | -- | 372.6K | 285.7K | 244.8K | -- |
| Diluted Shares Outstanding | 1.3M | 1.1M | 590.8K | -- | 372.6K | 285.7K | 244.8K | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $8.71M | $4.16M | $1.72M |
| **Cash & Short-Term Investments** | $8.71M | $4.16M | $1.72M |
| **Total Current Assets** | $9.89M | $5.38M | $1.89M |
| **Total Non-Current Assets** | $171K | $269K | $0 |
| **Total Assets** | $10.06M | $5.65M | $1.89M |
| Accounts Payable | $3.44M | $1.28M | $211K |
| Short-Term Debt | $5.25M | $0 | -- |
| **Total Current Liabilities** | $9.94M | $2.31M | $782K |
| **Total Non-Current Liabilities** | $86K | $206K | $0 |
| **Total Liabilities** | $10.02M | $2.51M | $782K |
| **Total Debt (incl. Leases)** | $5.45M | $322K | -- |
| Common Stock | $57.08M | $30.52M | $18.76M |
| Retained Earnings | -$64.35M | -$28.90M | -$17.75M |
| Accumulated Other Comp. Income | $11K | $0 | -- |
| **Total Stockholders' Equity** | -$68K | $3.13M | -- |
| Total Equity | $37K | $3.13M | $1.11M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $5.02M | $15.17M | $6.37M | $8.71M | $8.66M | $9.67M | $3.98M | $4.16M |
| **Cash & Short-Term Investments** | $5.02M | $15.17M | $6.37M | $8.71M | $8.66M | $9.67M | $3.98M | $4.16M |
| **Total Current Assets** | $6.37M | $16.98M | $7.28M | $9.89M | $9.78M | $11.00M | $5.09M | $5.38M |
| **Total Non-Current Assets** | $8.16M | $10.13M | $144K | $171K | $196K | $938K | $570K | $269K |
| **Total Assets** | $14.54M | $27.12M | $7.43M | $10.06M | $9.98M | $11.93M | $5.66M | $5.65M |
| Accounts Payable | $2.13M | $6.73M | $2.28M | $3.44M | $2.03M | $1.77M | $2.04M | $1.28M |
| Short-Term Debt | -- | -- | $2.34M | $5.25M | $6.79M | $4.70M | -- | $0 |
| **Total Current Liabilities** | $9.74M | $10.84M | $5.95M | $9.94M | $10.66M | $8.54M | $3.34M | $2.31M |
| **Total Non-Current Liabilities** | $15.28M | $18.00M | $45K | $86K | $125K | $142K | $174K | $206K |
| **Total Liabilities** | $25.03M | $28.84M | $6.00M | $10.02M | $10.78M | $8.69M | $3.51M | $2.51M |
| **Total Debt (incl. Leases)** | $108K | $137K | $2.52M | $5.45M | $7.02M | $4.97M | $295K | $322K |
| Common Stock | $80.60M | $74.30M | $67.11M | $57.08M | $4 | $37.83M | $32.91M | $30.52M |
| Retained Earnings | -$100.2M | -$85.01M | -$73.39M | -$64.35M | -$5 | -$40.18M | -$34.01M | -$28.90M |
| Accumulated Other Comp. Income | $40K | $61K | -$191K | $11K | $11K | -- | -- | $0 |
| **Total Stockholders' Equity** | -$10.54M | -$1.76M | $1.33M | -$68K | -$910K | -- | -- | $3.13M |
| Total Equity | -$10.49M | -$1.72M | $1.43M | $37K | -$805K | $3.25M | $2.15M | $3.13M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$35.44M | -$11.16M | -$5.31M |
| Stock-Based Compensation | $1.51M | $713K | $99K |
| Change in Payables | $924K | $809K | $79K |
| **Operating Cash Flow** | -$22.78M | -$10.25M | -$4.16M |
| **Investing Cash Flow** | -$4.62M | $0 | -- |
| Common Stock Issued | $9.79M | $5.47M | $0 |
| **Financing Cash Flow** | $31.94M | $12.69M | $5.61M |
| **Net Change in Cash** | $4.54M | $2.44M | $1.45M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$15.17M | -$11.68M | -$9.04M | -$8.18M | -$15.98M | -$6.18M | -$5.10M | -$3.54M |
| Stock-Based Compensation | $132K | $1.41M | $599K | $430K | $853K | $117K | $112K | $92K |
| Change in Payables | -$4.56M | $4.41M | -$1.26M | $1.30M | -$785K | -$251K | $656K | -- |
| **Operating Cash Flow** | -$15.94M | -$6.98M | -$8.97M | -$6.61M | -$6.76M | -$5.47M | -$3.94M | -$3.19M |
| Common Stock Issued | $0 | $0 | $0 | $0 | $0 | $6.01M | $3.78M | -- |
| **Financing Cash Flow** | $3.89M | $25.53M | $6.83M | $6.65M | $10.37M | $11.16M | $3.76M | $2.05M |
| **Net Change in Cash** | -$12.10M | $18.83M | -$2.34M | $43K | -$1.01M | $5.69M | -$182K | -- |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -355.9% | -- |
| Return on Assets (ROA) | -469.9% | -197.6% | -280.8% |
| Current Ratio | 1.00x | 2.33x | 2.42x |
| Quick Ratio | 0.88x | 1.81x | 2.20x |
| Debt to Equity | -- | 0.10x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -- | -3862.7% | -- | -- | -- | -- | -355.9% |
| Return on Assets (ROA) | -350.2% | -209.0% | -689.7% | -469.9% | -358.3% | -143.2% | -257.2% | -197.6% |
| Current Ratio | 0.65x | 1.57x | 1.22x | 1.00x | 0.92x | 1.29x | 1.53x | 2.33x |
| Quick Ratio | 0.52x | 1.40x | 1.07x | 0.88x | 0.81x | 1.13x | 1.19x | 1.81x |
| Debt to Equity | -- | -- | 1.90x | -- | -- | -- | -- | 0.10x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
